iA Global Asset Management Inc. Sells 238 Shares of DaVita Inc. (NYSE:DVA)

iA Global Asset Management Inc. cut its holdings in shares of DaVita Inc. (NYSE:DVA) by 5.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,930 shares of the company’s stock after selling 238 shares during the period. iA Global Asset Management Inc.’s holdings in DaVita were worth $543,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Newbridge Financial Services Group Inc. acquired a new position in DaVita during the 4th quarter worth $30,000. Principal Securities Inc. acquired a new position in DaVita during the 4th quarter worth $37,000. GAMMA Investing LLC acquired a new position in DaVita during the 4th quarter worth $60,000. Quent Capital LLC lifted its holdings in DaVita by 21.0% during the 1st quarter. Quent Capital LLC now owns 581 shares of the company’s stock worth $80,000 after buying an additional 101 shares in the last quarter. Finally, Quest Partners LLC acquired a new position in DaVita during the 4th quarter worth $74,000. 90.12% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on the company. StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 8th. Barclays increased their price target on DaVita from $133.00 to $150.00 and gave the company an “equal weight” rating in a research note on Monday, May 6th. TD Cowen increased their price target on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Finally, Truist Financial increased their price target on DaVita from $135.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, May 15th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $146.00.

DaVita Trading Up 1.2 %

Shares of DVA traded up $1.67 during trading hours on Friday, reaching $139.19. The stock had a trading volume of 261,883 shares, compared to its average volume of 830,385. The company has a quick ratio of 1.37, a current ratio of 1.43 and a debt-to-equity ratio of 7.95. DaVita Inc. has a 52 week low of $71.51 and a 52 week high of $147.93. The firm has a 50-day moving average of $140.70 and a 200 day moving average of $131.99. The company has a market cap of $12.21 billion, a P/E ratio of 15.48, a P/E/G ratio of 1.04 and a beta of 0.87.

DaVita (NYSE:DVA) last released its quarterly earnings data on Thursday, May 2nd. The company reported $2.38 EPS for the quarter, beating analysts’ consensus estimates of $1.95 by $0.43. DaVita had a net margin of 6.61% and a return on equity of 68.52%. The business had revenue of $3.07 billion during the quarter, compared to analysts’ expectations of $3.03 billion. During the same quarter in the prior year, the company earned $1.58 EPS. The firm’s quarterly revenue was up 6.9% on a year-over-year basis. On average, sell-side analysts expect that DaVita Inc. will post 9.62 earnings per share for the current fiscal year.

Insider Activity at DaVita

In other DaVita news, Director Barbara J. Desoer sold 5,030 shares of the stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $138.81, for a total transaction of $698,214.30. Following the completion of the transaction, the director now owns 10,954 shares in the company, valued at approximately $1,520,524.74. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 2.00% of the stock is owned by corporate insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.